◼ Archived
Business
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
Ionis Pharmaceuticals
3 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
Otsuka and Ionis report positive Phase 3 FUSION trial data for ulefnersen in treating a rare genetic form of ALS.
◼ Archived
Business
🔮 fades ✗
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
A failed clinical trial by AstraZeneca and Ionis for eplontersen raises critical questions about the efficacy of silencer drugs in treating heart disease.